NL300368I2 - Geïnactiveerd split influenzavirus van influenzastam A/Indonesia/05/2005 (H5N1) (PR8-IBCDC-RG2), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie - Google Patents

Geïnactiveerd split influenzavirus van influenzastam A/Indonesia/05/2005 (H5N1) (PR8-IBCDC-RG2), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie

Info

Publication number
NL300368I2
NL300368I2 NL300368C NL300368C NL300368I2 NL 300368 I2 NL300368 I2 NL 300368I2 NL 300368 C NL300368 C NL 300368C NL 300368 C NL300368 C NL 300368C NL 300368 I2 NL300368 I2 NL 300368I2
Authority
NL
Netherlands
Prior art keywords
pandemic
influenza
influenza strain
ibcdc
indonesia
Prior art date
Application number
NL300368C
Other languages
English (en)
Other versions
NL300368I1 (nl
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300368(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9916794.2A external-priority patent/GB9916794D0/en
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Publication of NL300368I1 publication Critical patent/NL300368I1/nl
Publication of NL300368I2 publication Critical patent/NL300368I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL300368C 1999-07-14 2008-11-13 Geïnactiveerd split influenzavirus van influenzastam A/Indonesia/05/2005 (H5N1) (PR8-IBCDC-RG2), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie NL300368I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14364599P 1999-07-14 1999-07-14
GBGB9916794.2A GB9916794D0 (en) 1999-07-16 1999-07-16 In vitro virus reconstitution
PCT/GB2000/002710 WO2001004333A1 (en) 1999-07-14 2000-07-14 In vitro reconstitution of segmented negative-strand rna viruses

Publications (2)

Publication Number Publication Date
NL300368I1 NL300368I1 (nl) 2009-01-05
NL300368I2 true NL300368I2 (nl) 2017-08-03

Family

ID=26315773

Family Applications (4)

Application Number Title Priority Date Filing Date
NL300294C NL300294I2 (nl) 1999-07-14 2007-09-21 In vitro reconstitutie van RNA-virussen met een gesegmenteerde negatieve streng
NL300301C NL300301I2 (nl) 1999-07-14 2007-09-21 In vitro reconstitutie van RNA-virussen met een gesegmenteerde negatieve streng
NL300369C NL300369I1 (nl) 1999-07-14 2008-11-13 In vitro reconstitutie van RNA-virussen met een gesegmenteerde negatieve streng
NL300368C NL300368I2 (nl) 1999-07-14 2008-11-13 Geïnactiveerd split influenzavirus van influenzastam A/Indonesia/05/2005 (H5N1) (PR8-IBCDC-RG2), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie

Family Applications Before (3)

Application Number Title Priority Date Filing Date
NL300294C NL300294I2 (nl) 1999-07-14 2007-09-21 In vitro reconstitutie van RNA-virussen met een gesegmenteerde negatieve streng
NL300301C NL300301I2 (nl) 1999-07-14 2007-09-21 In vitro reconstitutie van RNA-virussen met een gesegmenteerde negatieve streng
NL300369C NL300369I1 (nl) 1999-07-14 2008-11-13 In vitro reconstitutie van RNA-virussen met een gesegmenteerde negatieve streng

Country Status (12)

Country Link
EP (1) EP1194580B2 (nl)
AT (1) ATE353370T1 (nl)
AU (1) AU5998400A (nl)
CA (1) CA2379012C (nl)
CY (2) CY1106404T1 (nl)
DE (5) DE122007000061I2 (nl)
DK (1) DK1194580T4 (nl)
ES (1) ES2278621T5 (nl)
FR (1) FR08C0046I2 (nl)
LU (1) LU91367I2 (nl)
NL (4) NL300294I2 (nl)
WO (1) WO2001004333A1 (nl)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2400445T3 (es) 1998-06-12 2013-04-09 Mount Sinai School Of Medicine Virus atenuados con cadena de polaridad negativa con actividad antagonista de interferón alterada para uso como vacunas y productos farmacéuticos
WO2002083896A2 (en) * 2001-04-17 2002-10-24 Institut Pasteur Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
BRPI0307679A2 (pt) 2002-02-13 2016-11-08 Wisconsin Alumni Res Found vetor viral de influenza, vírus recombinate de influenza, molécula isolada de ácido nucleico e métodos para expressar um segmento heterólogo de ácido nucleico em uma célula e para preparar vírus semelhante a influenza incompetente na replicação.
FR2866031B1 (fr) * 2004-02-11 2012-10-19 David Francois Joseph Millet Chimere de virus pathogene emergent, medicament la contenant et utilisation en therapie antivirale
CA2559371C (en) 2004-03-09 2014-07-08 Chiron Corporation Influenza virus vaccines
WO2006083286A2 (en) 2004-06-01 2006-08-10 Mount Sinai School Of Medicine Of New York University Genetically engineered swine influenza virus and uses thereof
BRPI0518568A2 (pt) 2004-12-24 2008-11-25 Solvay Pharm Bv mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico
EP1855713B1 (en) 2005-02-15 2016-04-27 Mount Sinai School of Medicine Genetically engineered equine influenza virus and uses thereof
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
WO2007002008A2 (en) 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Methods and compositions for expressing negative-sense viral rna in canine cells
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
JP2009514850A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
EP2368572B1 (en) 2005-11-04 2020-03-04 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
KR20080069232A (ko) 2005-11-04 2008-07-25 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼
HUE037460T2 (hu) 2005-12-02 2018-08-28 Icahn School Med Mount Sinai Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk
KR20110110853A (ko) 2006-01-27 2011-10-07 노파르티스 파르마 아게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
US20100068223A1 (en) 2006-03-24 2010-03-18 Hanno Scheffczik Storage of Influenza Vaccines Without Refrigeration
DK2016194T3 (en) * 2006-04-19 2015-06-15 Medimmune Llc METHODS AND COMPOSITIONS FOR EXPRESSION OF VIRAL NEGATIVE SENSE RNA IN DOG CELLS
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
US8597661B2 (en) 2007-05-04 2013-12-03 Wisconsin Alumni Research Foundation Neuraminidase-deficient live influenza vaccines
US8043856B2 (en) 2007-06-14 2011-10-25 Wisconsin Alumni Research Foundation Adenoviral vectors for influenza virus production
EP2045323A1 (en) * 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2268309B1 (en) 2008-03-18 2015-01-21 Novartis AG Improvements in preparation of influenza virus vaccine antigens
EP2233568A1 (en) 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Novel method for generation of RNA virus
EP2987856B1 (en) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
CA2752039A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
EA201500910A1 (ru) 2009-02-10 2016-04-29 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
WO2010092477A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
WO2011014504A1 (en) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
US8828406B2 (en) 2009-07-30 2014-09-09 Icahn School Of Medicine At Mount Sinai Influenza viruses and uses thereof
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US9708373B2 (en) 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
JP2013529913A (ja) 2010-06-02 2013-07-25 アヴィール グリーン ヒルズ バイオテクノロジー リサーチ ディベロプメント トレード アクチエンゲゼルシャフト Ｒｎａウィルスの作製のための方法及びヘルパーウィルス
WO2013032942A1 (en) 2011-08-26 2013-03-07 Yoshihiro Kawaoka Influenza viruses with mutant pb2 gene segment as live attenuated vaccines
EA201490659A1 (ru) 2011-09-20 2014-11-28 Маунт Синай Скул Оф Медсин Вакцины против вируса гриппа и их применения
CA2852857A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
EP2708552A1 (en) 2012-09-12 2014-03-19 Medizinische Universität Wien Influenza virus
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
JP2016508133A (ja) 2012-12-18 2016-03-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
US20140274806A1 (en) 2013-03-15 2014-09-18 Synthetic Genomics Vaccines Influenza virus reassortment
WO2014115104A1 (en) * 2013-01-23 2014-07-31 Novartis Ag Influenza virus reassortment
NZ711946A (en) 2013-03-14 2020-05-29 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CN107073099B (zh) 2014-02-27 2022-09-27 默沙东公司 用于治疗癌症的联合方法
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
CL2014003146A1 (es) * 2014-11-20 2015-06-12 Univ Santiago Chile Método para producir virus arn monocatenario negativo; plásmido recombinante funcional en células animales, que consta de un esqueleto pss-urg; método de obtención de partículas virales; y uso para expresar arn, proteínas autógenas o exógenas al virus.
CA2974699A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
MX2017010908A (es) 2015-02-26 2017-12-07 Boehringer Ingelheim Vetmedica Gmbh Vacuna bivalente contra el virus de gripe porcina.
JP2018524323A (ja) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド 抗原がマッチしたインフルエンザワクチン
EP3764098B1 (en) 2015-07-07 2022-11-16 Seqirus UK Limited Influenza potency assays
US10494613B2 (en) 2015-08-28 2019-12-03 Wisconsin Alumni Research Foundation (Warf) Generation of infectious influenza viruses from virus-like particles
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
EP4022046A2 (en) 2019-08-27 2022-07-06 Wisconsin Alumni Research Foundation (WARF) Recombinant influenza viruses with stabilized ha for replication in eggs
CN111363727B (zh) * 2020-01-20 2021-09-24 武汉大学 携带幽门螺杆菌的重组流感病毒、宿主细胞及其制备方法与应用
EP3896077A1 (en) 2020-04-16 2021-10-20 Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH Influenza virus-like particles (vlps)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840520A (en) * 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
DK1185615T3 (da) * 1999-04-06 2007-11-05 Wisconsin Alumni Res Found Rekombinante influenzavirus til vacciner og genterapi

Also Published As

Publication number Publication date
DE60033284T2 (de) 2007-10-25
EP1194580A1 (en) 2002-04-10
LU91367I2 (fr) 2007-11-21
DE122007000070I1 (de) 2008-01-31
DE122008000057I1 (de) 2009-04-09
CY2007023I2 (el) 2009-11-04
NL300294I1 (nl) 2007-12-03
NL300369I1 (nl) 2009-01-05
CY2007023I1 (el) 2009-11-04
DE60033284D1 (de) 2007-03-22
ATE353370T1 (de) 2007-02-15
NL300301I2 (nl) 2008-10-01
CA2379012C (en) 2013-07-02
DK1194580T3 (da) 2007-04-10
WO2001004333A1 (en) 2001-01-18
ES2278621T5 (es) 2011-02-02
EP1194580B1 (en) 2007-02-07
DK1194580T4 (da) 2011-01-03
DE122007000061I2 (de) 2011-07-21
NL300368I1 (nl) 2009-01-05
DE122008000056I1 (de) 2009-04-09
AU5998400A (en) 2001-01-30
ES2278621T3 (es) 2007-08-16
CY1106404T1 (el) 2010-07-28
EP1194580B2 (en) 2010-08-25
FR08C0046I2 (fr) 2011-11-25
DE122007000061I1 (de) 2007-12-20
NL300294I2 (nl) 2008-10-01
FR08C0046I1 (fr) 2009-01-02
NL300301I1 (nl) 2008-01-02
DE60033284T3 (de) 2014-10-30
CA2379012A1 (en) 2001-01-18

Similar Documents

Publication Publication Date Title
NL300368I2 (nl) Geïnactiveerd split influenzavirus van influenzastam A/Indonesia/05/2005 (H5N1) (PR8-IBCDC-RG2), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie
NL300364I2 (nl) Geïnactiveerd split influenzavirus van influenzastam A/California/7/2009 (H1N1) (X-179A), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie
DE60233061D1 (de) Alphavirus replikon-vektorsysteme
CO5540349A2 (es) Preparacion vacunal de virus de influenza inactivado
ATE434035T1 (de) Lebender influenza impfstoff und verfahren zu seiner herstellung
ECSP055586A (es) Proceso para producir una preparación de trombina con virus inactivados
CY1108735T1 (el) Συστημα διαμολυνσης dna για την παραγωγη μολυσματικου αντικωδογονου rna ιου
FI971998A0 (fi) Menetelmä biologisten tuotteiden tuottamiseksi proteiinittomassa viljelmässä
DE60224843D1 (de) Herstellung von viren, virusisolaten, und impfstoffen